Cargando…
Dual Small-Molecule Targeting of Procaspase-3 Dramatically Enhances Zymogen Activation and Anticancer Activity
[Image: see text] Combination anticancer therapy typically consists of drugs that target different biochemical pathways or those that act on different targets in the same pathway. Here we demonstrate a new concept in combination therapy, that of enzyme activation with two compounds that hit the same...
Autores principales: | Botham, Rachel C., Fan, Timothy M., Im, Isak, Borst, Luke B., Dirikolu, Levent, Hergenrother, Paul J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954530/ https://www.ncbi.nlm.nih.gov/pubmed/24383395 http://dx.doi.org/10.1021/ja4124303 |
Ejemplares similares
-
Small-Molecule Procaspase-3 Activation Sensitizes
Cancer to Treatment with Diverse Chemotherapeutics
por: Botham, Rachel C., et al.
Publicado: (2016) -
Crystal Structure of Procaspase-1 Zymogen Domain Reveals Insight into
Inflammatory Caspase
Autoactivation
por: Elliott, J. Michael, et al.
Publicado: (2009) -
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers
por: Schlein, Lisa J., et al.
Publicado: (2019) -
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients
por: Joshi, Avadhut D., et al.
Publicado: (2017) -
Systems of Zymogen Activation
por: Milstone, J. Haskell
Publicado: (1969)